U.S. Contraceptives Drugs And Devices Market size, share, Growth, Trend, Insight Growth Analysis Technology Innovation, Opportunity, Industry Outlook | A at 5.6% CAGR Forecast – 2024
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that the unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the U.S. that contraceptive manufacturers can address. Moreover, with a no-cost coverage insurance policy for sterilization, growth for U.S. contraceptive drugs and devices market is limited.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/368
Statistics revealed by the United Nations in 2015, mentions that sterilization is a dominant contraceptive method in regions such as North America. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the advanced contraceptive methods available in the market. Therefore, various smart strategies adopted by companies marketing contraceptive drugs and devices in the U.S such as promotion through salesforce, social media promotion, awareness campaigns, and sampling is expected to propel the market growth. Moreover, the rising introduction of new male contraceptive products with a high success rate is further projected to shape the course of growth of the U.S. contraceptive drugs and devices market in the near future.
The global U.S. contraceptive drugs and devices market was valued at US$ 6,785.9 million in 2016 and is expected to expand at a CAGR of 5.6% during the forecast period (2016 – 2024)
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/368
Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market
Private companies have a high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long-acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing the overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories, and Cipla Limited are at a pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills due to the extensive promotion activities of these products.
Favorable reimbursement scenario and increasing adoption of contraceptives among the low and middle-income population is fostering the market growth
Long-acting reversible contraceptives (LARC) are given complete insurance coverage by the U.S. Affordable Care Act. However, oral pills that generate sustainable revenue are of interest to market players. Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much-anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).
Insurance coverage for devices also varies from state to state in the U.S. as few states have low Medicaid reimbursement rates than the cost of the device, while few states offer reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates a disparity in demand for certain contraceptives across regions in the U.S. Rising efforts to standardize the rule all over the country is projected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/us-contraceptives-drug-and-devices-market-to-register-low-cagr-of-56-with-patent-expiries-leading-to-plummeting-growth-213
Shifting Preference of user for modern contraceptive methods
A higher success rate and favorable reimbursement policies are encouraging women to opt for these methods over contraceptive pills. Moreover, increasing consumer awareness and rising accessibility to modern contraceptives methods is expected to increase during the forecast period. As per the United Nation’s 2015 report, 9 out of 10 married or in-union women opt for modern contraceptive methods. Furthermore, gynecologists and sexologists are recommending the use of long-acting reversible contraceptives for couples who do not plan to have a child in near future, owing to their high affectivity compared to conventional contraceptives such as oral hormonal pills.
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Product Type
- Market Trends
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Mergers and Acquisitions
- Technology Overview
- Promotion Initiatives/Campaigns
- Reimbursement Scenario
- Pipeline Analysis
- Market Dynamics
- U.S. Contraceptive Drugs and Devices Market, By Product Type, 2014 – 2024 (US$ Million)
- Introduction
- Market Share Analysis, 2015 and 2024 (%)
- Y-O-Y Growth Analysis, 2014 – 2024
- Segment Trends
- Drugs
- Introduction
- Market Share Analysis, 2015 and 2024 (%)
- Y-O-Y Growth Analysis, 2014 – 2024
- Segment Trends
- Oral Contraceptive Pills
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Contraceptive Injectables
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Topical Contraceptives
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Oral Contraceptive Pills
- Devices
- Introduction
- Market Share Analysis, 2015 and 2024 (%)
- Y-O-Y Growth Analysis, 2014 – 2024
- Segment Trends
- Male Devices
- Condoms
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Condoms
- Female Devices
- Condoms
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Contraceptive Diaphragms
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Contraceptive Sponges
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Contraceptive Vaginal Rings
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Intrauterine Devices
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Hormonal
- Copper-T
- Subdermal Contraceptive Implants
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2014 – 2024, (US$ Million)
- Condoms
- Male Devices
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Church & Dwight Co. Inc.
- Pfizer, Inc.
- Bayer AG
- Mayer Laboratories, Inc.
- The Female Health Company
- Merck & Co. Inc.
- Allergan Plc
- Cooper Surgical, Inc.
- Cipla Limited
- HLL Lifecare
- Teva Pharmaceutical Industries Ltd.
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
